PERRIGO Co plc (PRGO) Stock Analysis and Metrics

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0001585364

Market Cap 1.62 Bn

P/E -1.15

P/S 0.38

Div. Yield 0.10

ROIC (Qtr) -0.33

Total Debt (Qtr) 3.64 Bn

Revenue Growth (1y) (Qtr) -2.52

Add ratio to table...

About

PERRIGO Co plc operates as a leading global healthcare solutions company, specializing in the development, manufacture, and distribution of a wide range of pharmaceutical and consumer healthcare products. The company is deeply entrenched in the healthcare industry, catering to both the prescription and over-the-counter (OTC) markets. PERRIGO Co plc's operations span across multiple continents, with a significant presence in North America, Europe, and other international markets. The company's portfolio includes generic pharmaceuticals, OTC products,...

PERRIGO Co plc operates as a leading global healthcare solutions company, specializing in the development, manufacture, and distribution of a wide range of pharmaceutical and consumer healthcare products. The company is deeply entrenched in the healthcare industry, catering to both the prescription and over-the-counter (OTC) markets. PERRIGO Co plc's operations span across multiple continents, with a significant presence in North America, Europe, and other international markets. The company's portfolio includes generic pharmaceuticals, OTC products, and specialty products, all designed to meet the diverse healthcare needs of consumers and healthcare providers.

PERRIGO Co plc generates revenue through the sale of its extensive product portfolio, which includes a variety of branded and generic pharmaceuticals, OTC health and wellness products, and specialty products. The company serves a broad customer base, including retail pharmacies, distributors, healthcare providers, and consumers directly through various retail channels. The revenue model is built on a combination of high-volume sales of low-cost generic products and the sale of premium-priced branded products, allowing the company to cater to a wide range of market segments.

• Consumer Healthcare: This segment focuses on the development, manufacture, and distribution of OTC health and wellness products. The portfolio includes well-known brands that cater to various health needs, such as pain relief, allergy management, and digestive health. This segment serves consumers directly through retail channels, including pharmacies, supermarkets, and online platforms.

• Prescription Pharmaceuticals: PERRIGO Co plc's prescription pharmaceuticals segment specializes in the development, manufacture, and distribution of generic pharmaceuticals. The company produces a wide range of generic drugs that are essential for treating various medical conditions. This segment serves healthcare providers, pharmacies, and distributors, ensuring the availability of affordable healthcare solutions.

• Specialty Products: This segment includes the development, manufacture, and distribution of specialty pharmaceuticals and other healthcare products. The portfolio may include products that cater to specific medical needs or conditions, providing targeted solutions for patients and healthcare providers.

PERRIGO Co plc holds a strong position within the healthcare industry, competing with other major players in the pharmaceutical and consumer healthcare sectors. The company's competitive advantages include a diverse product portfolio, a robust global supply chain, and a strong focus on operational efficiency. PERRIGO Co plc's ability to leverage economies of scale in the purchase of materials and supplies further enhances its competitive position. The company's cooperative relationships with suppliers and its capacity to react effectively to sourcing challenges also contribute to its market standing. Additionally, PERRIGO Co plc's extensive experience in regulatory compliance and its ability to navigate complex approval processes for new products provide a strategic edge in the industry.

The company's customer base is diverse and spans across multiple channels, including retail pharmacies, distributors, healthcare providers, and consumers. PERRIGO Co plc's products are available through various retail channels, ensuring broad accessibility for consumers seeking healthcare solutions. The company's commitment to providing high-quality, affordable healthcare products positions it as a trusted partner for both healthcare providers and consumers.

Investment thesis

Bull case

Perrigo’s store‑brand over‑the‑counter portfolio has demonstrated resilient share‑gain momentum, even amid a broader consumer health softness that has weighed on peers. Over the last thirteen weeks the company has added 90 basis points of volume share in the U.S. across key categories such as smoking cessation, allergy, and women’s health, a trend that is rarely achieved by incumbent players in a highly competitive environment. Management’s narrative underscores that this growth is largely driven by disciplined execution, a robust multi‑price point strategy, and targeted A&P investments that have delivered incremental sales of approximately $30 million beyond forecasts. The fact that the company is able to capture additional share while its overall top line has slipped suggests a durable underlying demand that can be leveraged when market conditions normalize. {bullet} The company’s strategic 3S plan – stabilize, streamline, strengthen – has yielded tangible cost efficiencies that are likely to improve the margin profile over the next 12 months. Project Energize has already delivered $163 million in gross annual savings, comfortably exceeding the midpoint of the $140 million to $170 million target range, and the supply‑chain reinvention program is on track to generate an additional $150 million to $200 million in benefits by year‑end. These initiatives not only offset any compression from softer consumption but also create a margin cushion that can be re‑allocated to higher‑yielding initiatives such as brand building, digital expansion, and accelerated innovation pipelines. {bullet} Perrigo’s divestiture of the dermocosmetics business, scheduled for completion in 2026, will free up significant capital and further reduce leverage, enabling the firm to reinvest in core high‑margin OTC segments. The proceeds are earmarked for debt reduction, which will tighten the net debt to adjusted EBITDA ratio from the current 3.8x toward the company’s prior 3.5x target, thereby enhancing financial flexibility and supporting dividend stability. This deleveraging, coupled with the cash‑flow generation from the existing OTC business, positions Perrigo to fund new product launches and scale successful brands into new geographies with minimal financing costs. {bullet} While infant formula represents a smaller slice of Perrigo’s overall revenue (~10% of 2024 net sales), its strategic review could unlock hidden value. If the company decides to sell or spin off the unit, the transaction could unlock a valuation premium that reflects the lower risk profile of the remaining OTC portfolio and the potential for higher return on capital. The current $240 million investment that was paused can be reassessed against a clearer cost structure; if the unit is deemed non‑strategic, the company could avoid the opportunity cost of capital tied up in an underperforming segment, thereby freeing resources for higher‑growth initiatives. {bullet} Tariff exposure, which management estimates at $40–$50 million, is being mitigated through pricing adjustments and supply‑chain sourcing changes that the company claims are already underway. Even if the full impact is realized in the near term, the company’s operating margin is projected to hold near 15% in 2025, suggesting that the margin compression from tariffs will be absorbed without materially eroding profitability. Moreover, the firm’s diversified geographic footprint means that any adverse tariff adjustments in one region can be offset by stable performance elsewhere, reducing the overall risk to earnings. {bullet} The company’s investment in innovation, especially its focus on small‑price‑point molecules and the accelerated roll‑out of new products, indicates a pipeline that could capture additional share in categories where consumers are price‑sensitive. The management team’s emphasis on “highly focused innovation processes” signals a commitment to developing differentiated products that can command premium pricing within the store‑brand space, which historically yields better margins than national brands. If the company can successfully translate these pipeline initiatives into commercial success, the upside potential to organic net sales growth could be significant, especially as the broader OTC market begins to recover. {bullet} Finally, the market’s current focus on the negative aspects of the infant formula review may lead to an over‑discount of Perrigo’s OTC prospects. The narrative of a struggling infant formula unit, combined with a lowered 2025 EPS outlook, may eclipse the company’s solid share‑gain trajectory in the OTC arena. A rational reassessment of the company’s value, recognizing the momentum in OTC and the potential de‑leveraging benefits, could result in a more favorable valuation multiple that reflects the firm’s true growth trajectory.

Perrigo’s store‑brand over‑the‑counter portfolio has demonstrated resilient share‑gain momentum, even amid a broader consumer health softness that has weighed on peers. Over the last thirteen weeks the company has added 90 basis points of volume share in the U.S. across key categories such as smoking cessation, allergy, and women’s health, a trend that is rarely achieved by incumbent players in a highly competitive environment. Management’s narrative underscores that this growth is largely driven by disciplined execution, a robust multi‑price point strategy, and targeted A&P investments that have delivered incremental sales of approximately $30 million beyond forecasts. The fact that the company is able to capture additional share while its overall top line has slipped suggests a durable underlying demand that can be leveraged when market conditions normalize. {bullet} The company’s strategic 3S plan – stabilize, streamline, strengthen – has yielded tangible cost efficiencies that are likely to improve the margin profile over the next 12 months. Project Energize has already delivered $163 million in gross annual savings, comfortably exceeding the midpoint of the $140 million to $170 million target range, and the supply‑chain reinvention program is on track to generate an additional $150 million to $200 million in benefits by year‑end. These initiatives not only offset any compression from softer consumption but also create a margin cushion that can be re‑allocated to higher‑yielding initiatives such as brand building, digital expansion, and accelerated innovation pipelines. {bullet} Perrigo’s divestiture of the dermocosmetics business, scheduled for completion in 2026, will free up significant capital and further reduce leverage, enabling the firm to reinvest in core high‑margin OTC segments. The proceeds are earmarked for debt reduction, which will tighten the net debt to adjusted EBITDA ratio from the current 3.8x toward the company’s prior 3.5x target, thereby enhancing financial flexibility and supporting dividend stability. This deleveraging, coupled with the cash‑flow generation from the existing OTC business, positions Perrigo to fund new product launches and scale successful brands into new geographies with minimal financing costs. {bullet} While infant formula represents a smaller slice of Perrigo’s overall revenue (~10% of 2024 net sales), its strategic review could unlock hidden value. If the company decides to sell or spin off the unit, the transaction could unlock a valuation premium that reflects the lower risk profile of the remaining OTC portfolio and the potential for higher return on capital. The current $240 million investment that was paused can be reassessed against a clearer cost structure; if the unit is deemed non‑strategic, the company could avoid the opportunity cost of capital tied up in an underperforming segment, thereby freeing resources for higher‑growth initiatives. {bullet} Tariff exposure, which management estimates at $40–$50 million, is being mitigated through pricing adjustments and supply‑chain sourcing changes that the company claims are already underway. Even if the full impact is realized in the near term, the company’s operating margin is projected to hold near 15% in 2025, suggesting that the margin compression from tariffs will be absorbed without materially eroding profitability. Moreover, the firm’s diversified geographic footprint means that any adverse tariff adjustments in one region can be offset by stable performance elsewhere, reducing the overall risk to earnings. {bullet} The company’s investment in innovation, especially its focus on small‑price‑point molecules and the accelerated roll‑out of new products, indicates a pipeline that could capture additional share in categories where consumers are price‑sensitive. The management team’s emphasis on “highly focused innovation processes” signals a commitment to developing differentiated products that can command premium pricing within the store‑brand space, which historically yields better margins than national brands. If the company can successfully translate these pipeline initiatives into commercial success, the upside potential to organic net sales growth could be significant, especially as the broader OTC market begins to recover. {bullet} Finally, the market’s current focus on the negative aspects of the infant formula review may lead to an over‑discount of Perrigo’s OTC prospects. The narrative of a struggling infant formula unit, combined with a lowered 2025 EPS outlook, may eclipse the company’s solid share‑gain trajectory in the OTC arena. A rational reassessment of the company’s value, recognizing the momentum in OTC and the potential de‑leveraging benefits, could result in a more favorable valuation multiple that reflects the firm’s true growth trajectory.

Bear case

The strategic review of the infant formula business is a clear indicator that this segment no longer aligns with Perrigo’s core consumer health focus, and it may ultimately result in a divestiture or a complete exit from the unit. The unit’s revenue of roughly $360 million represents less than 10% of the company’s 2024 net sales, yet the associated capital expenditures and operational deficiencies—highlighted by regulatory warnings for bacterial contamination—imply a persistent risk that could erode future cash flows. The paused $240 million investment plan underscores that the company acknowledges the high cost of bringing the unit up to an acceptable standard, and any delay or failure to remediate these issues may lead to a write‑down or a forced sale at a discount, materially reducing shareholder value. {bullet} The ongoing class action litigation alleging that Perrigo misled investors about the value and condition of its infant formula business introduces a significant reputational and financial risk. If the allegations hold, the company could face substantial liability, potentially in the tens of millions, and a forced revaluation of the unit that could depress share price further. Even in the absence of a definitive settlement, the mere existence of the lawsuit can erode investor confidence and attract scrutiny from regulators, thereby affecting the company’s ability to raise capital or secure favorable financing terms. {bullet} Soft demand in the broader OTC market, driven by broader consumer health trends, has already resulted in a 4.4% decline in organic net sales for the quarter and a 1.6% drop in global OTC. Management’s statement that the consumption decline is “transitory” is contradicted by the persistent nature of the slowdown and the lack of structural evidence to support a rebound. The company’s reliance on a modest 0.6% growth in U.S. OTC volume against a backdrop of declining overall category consumption suggests that the upside is limited. In such a scenario, the company’s share‑gain achievements may be short‑lived, and the underlying revenue base may continue to shrink. {bullet} Tariff impacts of $40–$50 million, while currently being mitigated through pricing and sourcing, remain a significant pressure on gross margin. The company’s gross margin fell 110 basis points in the quarter, largely due to lower sales and unfavorable mix rather than input costs, but the introduction of tariffs adds an additional cost layer that could further compress margins if consumer demand does not recover quickly. The firm’s reliance on a single pricing strategy to offset tariff costs—namely price increases—may not be sustainable if competitors maintain lower price points, leading to potential loss of market share. {bullet} The company’s heavy focus on cost‑saving initiatives, while beneficial for short‑term margin improvement, may stifle long‑term growth if the savings are achieved at the expense of innovation and brand building. The emphasis on streamlining and reducing operational spend could limit the resources available for developing new products or expanding into new geographies. Over‑emphasis on cost control could also erode the company’s ability to compete in categories where differentiation and marketing spend are critical for capturing consumer loyalty, particularly in the highly price‑sensitive OTC space. {bullet} The planned divestiture of the dermocosmetics business, although aimed at reducing leverage, introduces uncertainty regarding the timing and potential proceeds. If the sale is delayed or priced below expectations, the anticipated reduction in net debt may not materialize as projected, keeping the company’s leverage higher than desired. Furthermore, the exit process itself could create operational disruptions, distract management, and divert attention from core OTC initiatives, thereby slowing the execution of the 3S plan and diminishing shareholder returns. {bullet} Finally, the company’s current guidance for fiscal 2025—revised organic net sales growth of minus 2% to minus 2.5% and EPS of $2.70 to $2.80—represents a contraction from previous expectations. This downward revision, driven largely by soft OTC consumption and the infant formula review, signals a cautious outlook that may dampen investor enthusiasm. Even with a reaffirmation of operating margins near 15%, the market may perceive the company as a defensive play with limited upside, especially when compared to peers that are experiencing robust growth in high‑margin categories such as personalized nutrition or advanced therapeutic OTCs.

The strategic review of the infant formula business is a clear indicator that this segment no longer aligns with Perrigo’s core consumer health focus, and it may ultimately result in a divestiture or a complete exit from the unit. The unit’s revenue of roughly $360 million represents less than 10% of the company’s 2024 net sales, yet the associated capital expenditures and operational deficiencies—highlighted by regulatory warnings for bacterial contamination—imply a persistent risk that could erode future cash flows. The paused $240 million investment plan underscores that the company acknowledges the high cost of bringing the unit up to an acceptable standard, and any delay or failure to remediate these issues may lead to a write‑down or a forced sale at a discount, materially reducing shareholder value. {bullet} The ongoing class action litigation alleging that Perrigo misled investors about the value and condition of its infant formula business introduces a significant reputational and financial risk. If the allegations hold, the company could face substantial liability, potentially in the tens of millions, and a forced revaluation of the unit that could depress share price further. Even in the absence of a definitive settlement, the mere existence of the lawsuit can erode investor confidence and attract scrutiny from regulators, thereby affecting the company’s ability to raise capital or secure favorable financing terms. {bullet} Soft demand in the broader OTC market, driven by broader consumer health trends, has already resulted in a 4.4% decline in organic net sales for the quarter and a 1.6% drop in global OTC. Management’s statement that the consumption decline is “transitory” is contradicted by the persistent nature of the slowdown and the lack of structural evidence to support a rebound. The company’s reliance on a modest 0.6% growth in U.S. OTC volume against a backdrop of declining overall category consumption suggests that the upside is limited. In such a scenario, the company’s share‑gain achievements may be short‑lived, and the underlying revenue base may continue to shrink. {bullet} Tariff impacts of $40–$50 million, while currently being mitigated through pricing and sourcing, remain a significant pressure on gross margin. The company’s gross margin fell 110 basis points in the quarter, largely due to lower sales and unfavorable mix rather than input costs, but the introduction of tariffs adds an additional cost layer that could further compress margins if consumer demand does not recover quickly. The firm’s reliance on a single pricing strategy to offset tariff costs—namely price increases—may not be sustainable if competitors maintain lower price points, leading to potential loss of market share. {bullet} The company’s heavy focus on cost‑saving initiatives, while beneficial for short‑term margin improvement, may stifle long‑term growth if the savings are achieved at the expense of innovation and brand building. The emphasis on streamlining and reducing operational spend could limit the resources available for developing new products or expanding into new geographies. Over‑emphasis on cost control could also erode the company’s ability to compete in categories where differentiation and marketing spend are critical for capturing consumer loyalty, particularly in the highly price‑sensitive OTC space. {bullet} The planned divestiture of the dermocosmetics business, although aimed at reducing leverage, introduces uncertainty regarding the timing and potential proceeds. If the sale is delayed or priced below expectations, the anticipated reduction in net debt may not materialize as projected, keeping the company’s leverage higher than desired. Furthermore, the exit process itself could create operational disruptions, distract management, and divert attention from core OTC initiatives, thereby slowing the execution of the 3S plan and diminishing shareholder returns. {bullet} Finally, the company’s current guidance for fiscal 2025—revised organic net sales growth of minus 2% to minus 2.5% and EPS of $2.70 to $2.80—represents a contraction from previous expectations. This downward revision, driven largely by soft OTC consumption and the infant formula review, signals a cautious outlook that may dampen investor enthusiasm. Even with a reaffirmation of operating margins near 15%, the market may perceive the company as a defensive play with limited upside, especially when compared to peers that are experiencing robust growth in high‑margin categories such as personalized nutrition or advanced therapeutic OTCs.

Segments Breakdown of Revenue (2025)

Disposal Group Name Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ZTS	Zoetis Inc.	52.41 Bn	19.60	5.54	9.04 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.83 Bn	25.23	2.08	16.81 Bn
3	UTHR	UNITED THERAPEUTICS Corp	25.40 Bn	19.03	7.98	-
4	NBIX	Neurocrine Biosciences Inc	12.96 Bn	27.02	4.53	-
5	HCM	HUTCHMED (China) Ltd	12.76 Bn	28.06	23.27	0.09 Bn
6	ELAN	Elanco Animal Health Inc	11.22 Bn	-48.11	2.38	4.02 Bn
7	ALKS	Alkermes plc.	5.52 Bn	22.80	3.74	-
8	LNTH	Lantheus Holdings, Inc.	5.51 Bn	23.64	3.57	0.57 Bn

Research Tools

PERRIGO Co plc (NYSE: PRGO)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Disposal Group Name Breakdown of Revenue (2025)

Peer comparison

Research Tools

PERRIGO Co plc (NYSE: PRGO)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Disposal Group Name Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password